Literature DB >> 10777030

The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile.

G A Mansoor1, W B White, E J McCabe, S Giacco.   

Abstract

We studied how closely changes in electronically monitored physical activity are reflected in changes in blood pressure and heart rate in a group of untreated hypertensive subjects. Thirty-nine hypertensive patients (office blood pressure > 140/ 90 mm Hg) of mean age 57 +/- 10 years (mean +/-SD) wore an ambulatory blood pressure monitor and a wrist actigraph simultaneously. Both average and peak activity for 5 min before each valid blood pressure reading were determined, as was average activity for awake and sleep periods, determined by patient kept diaries. For the overall group, awake and 24-h activities were inversely correlated to age (n = 39, r = -0.42; P = 0.01 and n = 39, r = -0.38; P = 0.01, respectively). No correlation was found between group awake activity and group-average blood pressure or heart rate. For individual patients, there was marked variation in the degree of correlation between awake activity measures (both peak and average) and blood pressure and heart rate. The strongest positive correlation was between activity levels and the heart rate-pressure product. Nondipper profile hypertensives had higher sleep activity than dipper hypertensives (44 +/- 28 units/min v 25 +/- 20 units/min, df = 37, t = 2.12; P = 0.04), but awake activity levels were similar. The higher sleep activity remained after adjustment for age. These findings indicate that the relationship between actigraphic activity and hemodynamic parameters is highly variable and that the rate-pressure product is the strongest correlate of short-term activity. Furthermore, hypertensives with the nondipper profile have higher sleep activity than dipper hypertensives. These findings stress the need for further study into the role of day-to-day activity in determining ambulatory blood pressure and heart rate variability.

Entities:  

Mesh:

Year:  2000        PMID: 10777030     DOI: 10.1016/s0895-7061(99)00147-8

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment.

Authors:  S Zacharieva; M Orbetzova; A Stoynev; R Shigarminova; M Yaneva; K Kalinov; E Nachev; A Elenkova
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 2.  Chronobiological considerations for exercise and heart disease.

Authors:  Greg Atkinson; Barry Drust; Keith George; Thomas Reilly; Jim Waterhouse
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

Review 3.  Ambulatory blood pressure monitoring in spinal cord injury: clinical practicability.

Authors:  Michèle Hubli; Andrei V Krassioukov
Journal:  J Neurotrauma       Date:  2014-01-30       Impact factor: 5.269

4.  Physical activity and hemodynamic reactivity in chronic kidney disease.

Authors:  Rajiv Agarwal; Robert P Light
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-15       Impact factor: 8.237

Review 5.  Relationships between sleep, physical activity and human health.

Authors:  Greg Atkinson; Damien Davenne
Journal:  Physiol Behav       Date:  2006-10-25

6.  Associations of Sleep Quality and Awake Physical Activity with Fluctuations in Nocturnal Blood Pressure in Patients with Cardiovascular Risk Factors.

Authors:  Manabu Kadoya; Hidenori Koyama; Masafumi Kurajoh; Mariko Naka; Akio Miyoshi; Akinori Kanzaki; Miki Kakutani; Takuhito Shoji; Yuji Moriwaki; Tetsuya Yamamoto; Masaaki Inaba; Mitsuyoshi Namba
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

Review 7.  Blunted nocturnal decline in blood pressure.

Authors:  L Michael Prisant
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

8.  Optimal timing for antihypertensive dosing: focus on valsartan.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.